Glycogen synthase kinase-3β, or a link between amyloid and tau pathology?

Genes, Brain and Behavior

Volumn 7, Issue SUPPL. 1, 2008, Pages 57-66

  Muyllaert, D ^a   Kremer, A ^a   Jaworski, T ^a   Borghgraef, P ^a   Devijver, H ^a   Croes, S ^a   Dewachter, I ^a   Van Leuven, F ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Amyloid; Glycogen synthase kinase; Tau; Transgenic mice

Indexed keywords

AMYLOID PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; ISOENZYME; LITHIUM; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ANALYSIS; ENZYME PHOSPHORYLATION; MOOD DISORDER; MOUSE; NEOPLASM; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; REGULATORY MECHANISM; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HUMANS; ISOENZYMES; LITHIUM; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES;

MUS MUSCULUS;

EID: 37749047236     PISSN: 16011848     EISSN: 1601183X     Source Type: Journal    
DOI: 10.1111/j.1601-183X.2007.00376.x     Document Type: Conference Paper

References (82)

1. Alvarez, G., Munoz-Montano, J.R., Satrustegui, J., Avila, J., Bogonez, E. Diaz-Nido, J 1999) Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett 453, 260 264.
2. Aplin, A.E., Jacobsen, J.S., Anderton, B.H. Gallo, J.M 1997) Effect of increased glycogen synthase kinase-3 activity upon the maturation of the amyloid precursor protein in transfected cells. Neuroreport 8, 639 643.
3. Avila, J., Santa-Maria, I., Perez, M., Hernandez, F. Moreno, F 2006) Tau phosphorylation, aggregation, and cell toxicity. J Biomed Biotechnol 3, 74539.
4. Balaraman, Y., Limaye, A.R., Levey, A.I. Srinivasan, S 2006) Glycogen synthase kinase 3beta and Alzheimer's disease: pathophysiological and therapeutic significance. Cell Mol Life Sci 63, 1226 1235.
5. Bellon, S., Fitzgibbon, M.J., Fox, T., Hsiao, H.M. Wilson, K.P 1999) The structure of phosphorylated p38 gamma is monomeric and reveals a conserved activation-loop conformation. Structure 7, 1057 1065.
6. Berridge, J.M., Downes, C.P. Hanley, M.R 1989) Neural and developmental actions of lithium: a unifying hypothesis. Cell 59, 411 419.
7. Billings, L.M., Green, K.N., McGaugh, J.L. Laferla, F 2007) Learning decreases Abeta*56 and tau pathology and ameliorates behavioral decline in 3xTg-ED mice. J Neurosci 27, 751 761.
8. Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A. Hof, P.R 2000) Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 33, 95 130.
9. Caccamo, A., Oddo, S., Tran, L.X. LaFerla, F.M 2007) Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 170, 1669 1675.
10. Cho, J.H. Johnson, G.V 2003) Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem 278, 187 193.
11. Cho, J.H. Johnson, G.V.W 2004) Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3b (GSK3b) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem 88, 349 358.
12. Cohen, P. Frame, S 2001) The renaissance of GSK3. Nat Rev Mol Cell Biol 2, 769 776.
13. Dajani, R., Fraser, E., Roe, S.M., Young, N., Good, V., Dale, T.C. Pearl, L.H 2001) Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105, 721 732.
14. De Sarno, P., Li, X. Jope, R.S 2002) Regulation of Aktand glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43, 1158 1164.
15. Doble, B.W. Woodgett, J.R 2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116, 1175 1186.
16. Dunn, N 2005) Does lithium therapy protect against the onset of dementia? Alzheimer Relat Disord 19, 220 222.
17. Engel, T., Goni-Oliver, P., Lucas, J.J., Avila, J. Hernandez, F 2006) Chronic lithium administration to FTDP-17 tau and GSK-3β overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 99, 1445 1455.
18. Feyt, C., Kienlen-Campard, P., Leroy, K., N'Kuli, F., Courtoy, P.J., Brion, J.P. Octave, J.N 2005) Lithium chloride increases the production of Amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3. J Biol Chem 280, 33220 33227.
19. Fiol, C.J., Mahrenholz, A.M., Wang, Y., Roeske, R.W. Roach, P.J 1987) Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J Biol Chem 262, 14042 14048.
20. Goedert, M. Ghetti, B 2007) Alois Alzheimer: his life and times. Brain Pathol 17, 57 62.
21. Goldsbury, C., Mocanu, M.M., Thies, E., Kaether, C., Haass, C., Keller, P., Biernat, J., Mandelkow, E. Mandelkow, E.M 2006) Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-beta peptides. Traffic 7, 873 888.
22. Goode, N., Hughes, K., Woodgett, J.R. Parker, P.J 1992) Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J Biol Chem 267, 16878 16882.
23. Grimes, C.A. Jope, R.S 2001) The multifaceted roles of glycogen synthase kinase-3beta in cellular signaling. Prog Neurobiol 65, 391 426.
24. ter Haar, E., Coll, J.T., Austen, D.A., Hsiao, H.M., Swenson, L. Jain, J 2001) Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct Biol 8, 593 596.
25. Hernandez, F., Perez, M., Lucas, J.J., Mata, A.M., Bhat, R. Avila, J 2004) Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35: implications for Alzheimer's disease. J Biol Chem 279, 3801 3806.
26. Hoeflich, K.P., Luo, J., Rubie, E.A., Tsao, M.S., Jin, O. Woodgett, J.R 2000) Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406, 86 90.
27. Hong, M., Chen, D.C., Klein, P.S. Lee, V.M 1997) Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 272, 25326 25332.
28. Hooper, C., Markevich, V., Plattner, F., Killick, R., Schofield, E., Engel, T., Hernandez, F., Anderton, B., Rosenblum, K., Bliss, T., Cooke, S.F., Avila, J., Lucas, J.J., Giese, K.P., Stephenson, J. Lovestone, S 2007) Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci 25, 81 86.
29. Hughes, K., Nikolakaki, E., Plyte, S.E., Totty, N.F. Woodgett, J.R 1993) Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation. EMBO J 12, 803 808.
30. Ilouz, R., Kowalsman, N., Eisenstein, M. Eldar-Finkelman, H 2006) Identification of novel glycogen synthase kinase-3beta substrate-interacting residues suggests a common mechanism for substrate recognition. J Biol Chem 281, 30621 30630.
31. Iqbal, K. Grundke-Iqbal, I 2005) Metabolic-signal transduction hypothesis of Alzheimer's disease and other tauopathies. Acta Neuropathol (Berl) 109, 25 31.
32. Ishiguro, K., Takamatsu, M., Tomizawa, K., Omori, A., Takahashi, M., Arioka, M., Uchida, T. Imahori, K 1992) Tau protein kinase I converts normal tau protein into A68-like component of paired helical filaments. J Biol Chem 267, 10897 10901.
33. Ishizawa, T., Sahara, N., Ishiguro, K., Kersh, J., McGowan, E., Lewis, J., Hutton, M., Dickson, D.W. Yen, S.H 2003) Co-localization of glycogen synthase kinase-3 with neurofibrillary tangles and granulovacuolar degeneration in transgenic mice. Am J Pathol 163, 1057 1067.
34. Itoh, K., Tang, T.L., Neel, B.G. Sokol, S.Y 1995) Specific modulation of ectodermal cell fates in Xenopus embryos by glycogen synthase kinase. Development 121, 3979 3988.
35. Jackson, G.R., Wiedau-Pazos, M., Sang, T.K., Wagle, N., Brown, C.A., Massachi, S. Geschwind, D.H 2002) Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34, 509 519.
36. Jiang, H., Guo, W., Liang, X. Rao, Y 2005) Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators. Cell 120, 123 135.
37. Johnson, G.V. Stoothoff, W.H 2004) Tau phosphorylation in neuronal cell function and dysfunction (Review). J Cell Sci 117, 5721 5729.
38. Jope, R.S. Johnson, G.V 2004) The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 29, 95 102.
39. Kim, W.Y., Zhou, F.Q., Zhou, J., Yokota, Y., Wang, Y.M., Yoshimura, T., Kaibuchi, K., Woodgett, J.R., Anton, E.S. Snider, W.D 2006) Essential roles for GSK-3s and GSK-3-primed substrates in neurotrophin-induced and hippocampal axon growth. Neuron 52, 981 996.
40. Kirschenbaum, F., Hsu, S.C., Cordell, B. McCarthy, J.V 2001) Substitution of a glycogen synthase kinase-3beta phosphorylation site in presenilin 1 separates presenilin function from beta-catenin signalling. J Biol Chem 276, 7366 7375.
41. Klein, P.S. Melton, D.A 1996) A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93, 8455 8459.
42. Kockeritz, L., Doble, B., Patel, S. Woodgett, J.R 2006) Glycogen synthase kinase-3-an overview of an over-achieving protein kinase. Curr Drug Targets 7, 1377 1388.
43. Leroy, K. Brion, J.P 1999) Developmental expression and localization of glycogen synthase kinase-3beta in rat brain. J Chem Neuroanatom 16, 279 293.
44. Liang, M.H. Chuang, D.M 2006) Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J Biol Chem 281, 30479 30484.
45. Liang, M.H. Chuang, D.M 2007) Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival. J Biol Chem 282, 3904 3917.
46. Liu, C., Li, L., Semenov, M., Han, C., Baeg, G.H., Tan, Y., Zhang, Z., Lin, X. He, X 2002) Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108, 837 847.
47. Lochhead, P.A., Kinstrie, R., Sibbet, G., Rawjee, T., Morrice, N. Cleghon, V 2006) A chaperone-dependent GSK3β transitional intermediate mediates activation-loop autophosphorylation. Molecular Cell 24, 627 633.
48. Mandelkow, E.M 1993) Microtubule-associated protein tau, paired helical filaments, and phosphorylation. Ann N Y Acad Sci 695, 209 216.
49. Mazanetz, M.P. Fisher, P.M 2007) Untangling tau hyperphosphorylation in drug design for neurodegenrative diseases. Nat Rev Drug Discov 6, 464 479.
50. Moechars, D., Dewachter, I., Lorent, K., Reverse, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Van den Haute, C., Checler, F., Godaux, E., Cordell, B. Van Leuven, F 1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274, 6483 6492.
51. Muyllaert, D., Terwel, D., Borghgraef, P., Devijver, H., Dewachter, I. Van Leuven, F 2006) Transgenic mouse models for Alzheimer's disease: the role of GSK-3β in combined amyloid and tau-pathology. Rev Neurol (Paris) 162, 903 907.
52. Nakashima, H., Ishihara, T., Suguimoto, P., Yokota, O., Oshima, E., Kugo, A., Terada, S., Hamamura, T., Trojanowski, J.Q., Lee, V.M. Kuroda, S 2005) Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol (Berl) 110, 547 556.
53. Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., Burns, M., Krishnamurthy, P., Wen, Y., Bhat, R., Lewis, J., Dickson, D. Duff, K 2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102, 6990 6995.
54. Papadopoulou, D., Bianchi, M.W. Bourouis, M 2004) Functional studies of shaggy/glycogen synthase kinase 3 phosphorylation sites in Drosophila melanogaster. Mol Cell Biol 24, 4909 4919.
55. Pei, J.J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B. Cowburn, R.F 1999) Distribution of active glycogen synthase kinase 3beta (GSK-3β) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58, 1010 1019.
56. Peineau, S., Taghibiglou, C., Bradley, C., Wong, T.P., Liu, L., Lu, J., Lo, E., Wu, D., Saule, E., Bouschet, T., Matthews, P., Isaac, J.T., Bortolotto, Z.A., Wang, Y.T. Collingridge, G.L 2007) LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53, 703 717.
57. Phiel, C., Wilson, C., Lee, V. Klein, P 2003) GSK-3α regulates production of Alzheimer's disease amyloid-β peptides. Nature 423, 435 439.
58. Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., Gerstein, H., Yu, G.Q. Mucke, L 2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750 754.
59. Rockenstein, E., Torrance, M., Adam, A., Mante, M., Bar-on, P., Rose, J.B., Crews, L. Masliah, E 2007) Neuroprotective effects of regulators of the GSK-3β signalling pathway in a transgenic model for Alzheimer's disease are associated with reduced APP phosphorylation. Neurobiol Dis 27, 1981 1991.
60. Ryves, W.J. Harwood, A.J 2001) Lithium inhibits glycogensynthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 280, 720 725.
61. Salas, T.R., Reddy, S.A., Clifford, J.L., Davis, R.J., Kikuchi, A., Lippman, S.M. Menter, D.G 2003) Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. J Biol Chem 278, 41338 41346.
62. Sennvik, K., Boekhoorn, K., Lasrado, R., Terwel, D., Verhaeghe, S., Korr, H., Schmitz, C., Tomiyama, T., Mori, H., Krugers, H., Joels, M., Ramakers, G., Lucassen, P. Van Leuven, F 2007) Tau-4R suppresses proliferation and promotes neuronal differentiation in the hippocampus of tau knock-in/knock-out mice. FASEB J 21, 2149 2161.
63. Spittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen, I., Geerts, H., Mercken, M., Sciot, R., Van Lommel, A., Loos, R. Van Leuven, F 1999) Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 155, 2153 2165.
64. Spittaels, K., Van den Haute, C., Van Dorpe, J., Geerts, H., Mercken, M., Bruynseels, K., Lasrado, R., Vandezande, K., Laenen, I., Boon, T., Van Lint, J., Vandenheede, J., Moechars, D., Loos, R. Van Leuven, F 2000) Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J Biol Chem 275, 41340 41349.
65. Spittaels, K., Van den Haute, C., Van Dorpe, J., Terwel, D., Vandezande, K., Lasrado, R., Bruynseels, K., Irizarry, M., Verhoye, M., Van Lint, J., Vandenheede, J.R., Ashton, D., Mercken, M., Loos, R., Hyman, B., Van der Linden, A., Geerts, H. Van Leuven, F 2002) Neonatal neuronal overexpression of glycogen synthase kinase-3 beta reduces brain size in transgenic mice. Neuroscience 113, 797 808.
66. Stambolic, V., Ruel, L. Woodgett, J.R 1996) Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6, 1664 1668.
67. Su, Y., Ryder, J., Li, B., Wu, X., Fox, N., Solenberg, P., Brune, K., Paul, S., Zhou, Y., Liu, F. Ni, B 2004) Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43, 6899 6908.
68. Sun, X., Sato, S., Murayama, M., Park, J.M., Yamaguchi, H. Takashima, A 2002) Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 321, 61 64.
69. Takashima, A 2006) GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 9, 309 317.
70. Takashima, A., Noguchi, K., Sato, K., Hoshino, T. Imahori, K 1993) Tau protein kinase I is essential for amyloid b-protein-induced neurotoxicity. Proc Natl Acad Sci U S A 90, 7789 7793.
71. Takashima, A., Murayama, M., Murayama, O., Kohno, T., Honda, T., Yasutake, K., Nihonmatsu, N., Mercken, M., Yamaguchi, H., Sugihara, S. Wolozin, B 1998) Presenilin 1 associates with glycogen synthase kinase-3b and its substrate tau. Proc Natl Acad Sci U S A 95, 9637 9641.
72. Terao, T., Nakano, H., Inoue, Y., Okamoto, T., Nakamura, J. Iwata, N 2006) Lithium and dementia: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30, 1125 1128.
73. Terwel, D., Dewachter, I. Van Leuven, F 2002) Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease. Neuromolecular Med 2, 151 165.
74. Terwel, D., Lasrado, R., Snauwaert, J., Vandeweert, E., Van Haesendonck, C., Borghgraef, P. Van Leuven, F 2005) Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem 280, 3963 3973.
75. Twomey, C. McCarthy, J.V 2006) Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate. FEBS Lett 580, 4015 4020.
76. Uemura, K., Kuzuya, A., Shimozono, Y., Aoyagi, N., Ando, K., Shimohama, S. Kinoshita, A 2007) GSK3beta activity modifies the localization and function of presenilin 1. J Biol Chem 282, 15823 15832.
77. Van Dorpe, J., Smeijers, L., Dewachter, I., Nuysens, D., Spittaels, K., Van Den Haute, C., Mercken, M., Moechars, D., Laenen, I., Kuipéri, C., Bruynseels, K., Tesseur, I., Loos, R., Vanderstichele, H., Checler, F., Sciot, R. Van Leuven, F 2000) Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the London mutant of human APP in neurons. Am J Pathol 157, 1283 1298.
78. Van Leuven, F 2000) Single and multiple transgenic mice as models for Alzheimer's disease. Prog Neurobiol 61, 305 312.
79. Welsh, G.I., Miyamoto, S., Price, N.T., Safer, B. Proud, C.G 1996) T-cell activation leads to rapid stimulation of translation initiation factor eIF2B and inactivation of glycogen synthase kinase-3. J Biol Chem 271, 11410 11413.
80. Woodgett, J.R 1990) Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J 9, 2431 2438.
81. York, D.J., Ponder, J.W. Majerus, P.W 1995) Definition of a metal-dependent/Li(+) inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc Natl Acad Sci U S A 92, 5149 5153.
82. Yoshimura, T., Kawano, Y., Arimura, N., Kawabata, S., Kikuchi, A. Kaibuchi, K 2005) GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120, 137 149.